In summary, CD8+ T cells were activated and produced stronger anti-tumor responses post-NICT, reflecting that NICT for ESCA may induce antigen exposure, thereby restoring the anti-tumor immune efficacy. The gene discussed is CD8A; the disease is neoplasm.